AtriCure, Inc.

AtriCure develops and markets surgical devices and therapies designed to treat atrial fibrillation, manage the left atrial appendage, and control post-operative pain. Its primary solutions include cardiac ablation platforms utilizing radiofrequency and cryogenic energy, left atrial appendage exclusion systems under the AtriClip brand, and cryoablation probes for cryo nerve block. The company offers these technologies to medical centers and specialized clinicians, including cardiac and thoracic surgeons as well as electrophysiologists, for use in open-heart, minimally invasive, and amputation procedures.

The business commercializes its product portfolio through a direct sales organization across the United States, Germany, France, the United Kingdom, the Benelux region, Australia, and Canada. Additionally, third-party distributors market and distribute these surgical devices to medical facilities in other international territories. The provided report does not state the company's corporate headquarters, facility counts, or founding date.

Summary of the business section of AtriCure's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had approximately 1,350 employees.”